thymocyte globulin (ATG) in 7 recipients. Two of 16 (12.5%) PRA negative patients developed acute rejection (AR) episodes. Of PRA positive group (16 recipients) only one was DSA positive (6.2%) of PRA positive group, only 6 were transplanted (4 were given induction with BSA, two recipients got ATG induction. Two recipients out of 6 (33%) from PRA positive group who were transplanted had acute rejection (one had evidence of acute cellular rejection and another had glomerulitis on allograft histology) despite being CDC cross match negative. PRA positivity was associated with increased acute rejection episodes. On SA antibody assay, three recipients showed antibody against donor class-II antigens by single bead Luminex assay. All these three patients with single antigen DSA positivity developed acute rejection. All these three recipients showed no donor specific antibody pre transplant and CDC cross match against donor was also negative at the time of kidney transplantation.
Introduction
Body initiates cellular and humoral antibody responses when any infection occurs and our immune response has been developed for fighting foreign antigens like bacterial infections. In the case of organ transplantation, immune system may mount immune response to allograft kidney from the donor. 1 The immune responses are stimulated by donor antigens which are presented by antigen presenting cells (APC) of recipient. PRA gives estimate of immune responder status of recipient. Anti HLA sensitization could occur due to blood transfusion, pregnancy and previous transplant. 2 In the absence of history of sensitization, some recipients could show cross reacting anti-HLA IgM antibodies. 3 Anti-HLA sensitization can be detected by panel reactive antibody screening (PRA). PRA testing involves screening serum of a prospective recipient against a panel of cells as targets for anti HLA antibodies. Reactivity is expressed as percent positivity. Donor specific anti HLA antibodies are an indicator of donor specific sensitization which could trigger rejection. 4 HLA sensitization of recipient can be measured by PRA (panel reactive antibodies). The recipient serum's reaction with the screening panel of cells and the percentage of panel of target cells that react is termed PRA percent. PRA measurement is an indicator of broad sensitization and immune reactivity of a recipient. Donor specific antibody (DSA) is more specific in detecting sensitization against a particular donor. Antibodies are most commonly directed against human leukocyte antigen (HLA)/major-histocompatibility-complex (MHC) class I and II antigens. 5 HLA class I antigens are expressed on all nucleated cells, whereas HLA class II antigens are restricted to antigen-presenting cells (B lymphocytes, dendritic cells) and endothelial cells. Post transplant, donor specific HLA antibodies contribute to acute humoral (antibody mediated) rejection characterised by rapid graft dysfunction, accompanied by the presence of circulating anti-donor HLA antibodies. 6 
Material and method
All these 46 kidney transplant recipients were complement dependant cytotoxicity (CDC) crossmatch negative at room, warm, and cold temperature before transplantation. Panwl reactive antibodies (PRA), donor specific antibody (DSA) (Lifecode, Gen-Probe) were done on luminex platform.
Luminex system
The basic fundamental of the luminex technology is the ability to measure multiple analytes simultaneously in a single reaction well. In luminex technology, molecular interactions occur and are detected on the surface of microspheres presently up to 100. Different microsphere sets can be combined into a single well replaced by conventional multi well format. The size of microspheres is polystyrene (5e6 micron size). These microspheres were color coded using a mixture of different fluorescent intensities of two dyes, one was red and another was infrared. Microspheres shut and trap the unique ratio of dyes inside the beads. When they bind to the sample and pass through the luminex laser in the presence of sheath fluid stream, first the classical laser excites the fluorochromes imbedded inside the microspheres and ultimately allow for identification of each bead. Then the second laser (reporter laser) excites the fluorescent molecules to the bead surface and finally allow for reaction to positive or negative in the assay. Reporter laser emission is then converted into intensity units by the photo multiplier tube (PMT) and the photo bodies interpret the signals emitted from the classification laser. 7 Luminex fluoroanalyzers perform multiplex bead antibody assays and provide improved ability to establish antibody specificity, increased the accuracy of assays. 8 Luminex fluoroanalyzers perform multiplex bead antibody assays for anti-HLA antibodies using a solid-phase platform which includes pooled antigens, phenotype panel and single-antigen beads. 8 The pooled antigen assay serves as a screening if anti-HLA antibodies are present or absent (PRA, DSA screening), without offering information on antibody specificity.
The phenotype panel gives an objective measure of PRA percent value and determines antibody specificity.
The single antigen bead is typically used to validate antibody specificities initially derived from panel testing. Single -antigen bead also gives measure of antibody strength. Luminex platform is a powerful technology for HLA antibody detection; but there are some drawbacks which require welleducated analysis and interpretation of data in critical cases. In addition, Luminex has become an important tool to identify clinically relevant antibodies. 9 
4.
CDC crossmatch
Complement dependent cytotoxicity (CDC)
Complement dependant cytotoxicity (CDC) cross match test was first standardized by Terasaki in 1960's. 10 It is used to detect the donor specific antibodies against the recipient. Patel and Terasaki developed the CDC crossmatch for pretransplant donor recipient evaluation. If the result of the CDC cross match is positive, then transplantation with that donor is not advised. 11 CDC detects complement dependent anti HLA specific antibodies. 10 CDC test is based on donor lymphocytotoxicity testing mediated by rabbit complement. It is performed by incubating recipient serum with donor lymphocytes and checking for donor lymphocytotoxicity after adding rabbit complement. CDC has limitation like a possibility of complement fixing antibodies which can result in donor lympho cytotoxicity in absence of donor specific anti HLA antibody. Donor T and B lymphocytes are added to the recipient serum in the presence of complement, if donor cells are lysed then CDC is taken as positive and if they is no lysis then CDC is considered negative.
5.
Donor specific antibody (DSA) DSA screening done by (Lifecodes,Gen-Probe) uses donor lysate and detects donor specific anti-HLA class I, class II antibodies but fails to give the HLA specificities. 12 The mixture of the bead conjugated with monoclonal antibodies which are an identification for HLA class-I and class-II. Control beads are also there in the mixture of beads to identify the background in the assay and identify that conjugated must be used in the assay. 13 The bead is mixed with donor lysate and then with recipient serum to identify the DSA target for antibodies in the recipient serum.
Single antigen (SA)
The solid phase assays like (single antigen bead assay) SAB, also known as virtual crossmatch detect anti-HLA antibodies against the donor. In single antigen bead assay, the main advantage is increased sensitivity and specificity of the results. 14 Assay beads are mixed with recipient serum and then labeled with phycoerythrin (PE) conjugated with goat anti-human IgG antibody. The signal intensity of each bead is compared with negative control to identify for negative or positive reaction in the assay. 16
Anti-Thymocyte Globulin (ATG) or Basiliximab induction
Anti-Thymocyte Globulin (ATG) or Basiliximab induction were used in our center when recipients were going for transplantation to prevent rejection. These induction agents were chosen keeping in mind the clinical status of recipient. These modern immunosuppressants give minimum nephrotoxicity and protect the graft from rejection. 17 Anti-Thymocyte Globulin (ATG) is an anti-human T cell antibody used to prevent and treat acute rejection in kidney transplantation. Induction with ATG is associated with a reduction in the occurrence of donor specific DSA and AMR when compared with induction with Basiliximab. 18 Basiliximab is a mouse-human monoclonal antibody to the a-chain (CD25) of the IL-2 receptor of T cells. Basiliximab binds to CD25 thus blocking IL-2 from binding to activated lymphocytes. Basiliximab is used to prevent acute rejections in kidney transplantation. 19 IL-2 receptor monoclonal antibodies and ATG induction protocols have been used with the objective of reducing or abolishing the CNI nephrotoxicity and to minimize or avoid steroid use in the standard immunosuppression protocols.
Results
All the 46 kidney transplant recipients underwent PRA screening by luminex. They were divided in to two groups (Table 1 ) -Gr-I (PRA negative) n ¼ 30, 65%. Gr-II (PRA Positive) n ¼ 16, 35%. In PRA negative group, only 3 patients (10%) were DSA positive; one against class I and two recipients against class II HLA antigens ( Fig. 1 ). Of the PRA negative group; 16 patients received kidney transplantation. Induction with Basiliximab (BSA) was given in 9 and by Anti-thymocyte globulin (ATG) in 7 recipients. Two of 16 (12.5%) PRA negative patients developed acute rejection (AR) episodes. Of PRA positive group (n ¼ 16) recipients, (34%) only one was DSA positive (6.2%). Of PRA positive group, only 6 were transplanted (4 were given induction with BSA, two recipients got ATG induction). Two recipients out of 6 (33%) from PRA positive group who were transplanted had acute rejection (one had evidence of acute cellular rejection and another had glomerulitis on allograft histology). Of patients tested, three recipients showed antibody against donor class-II antigens on single bead Luminex assay. All these 3 patients with single antigen class II DSA positivity developed acute rejection. In all these three recipients, CDC cross match was negative at the time of kidney transplantation.
Discussion
CDC is traditionally considered gold standard method for donor and recipient compatibility for transplantation. 20 Pre transplant study done at our center showed that all these 46 recipients were CDC negative. DSA by Gen-probe (using donor lysate) and PRA screening showed no co-relation with each other. In PRA negative group there were less number of AR episodes as compared to PRA positive group. So these tests do not always predict the rejection episodes. In solid-phase immunoassays DSA and PRA screening are used to detect anti HLA antibodies, SAB assay is a virtual cross match which is based on donor tissue typing and recipient anti HLA antibody compatibility. It is also important to keep in mind the limitation of solid phase assays when considering for pre or post transplant screening. 21 DSA screening tests tend to identify anti HLA antibodies for class I and class II and their titer. After transplant if any of these classes of donor specific antibodies develop then the risk for AMR increases. To standardize results, labs need to identify cut off (MFI) values so that it can be compared with traditional CDC compatibility, previous results and negative DSA values. 22 The clinical significance of such a scenario can best be addressed by solid phase assay testing to avoid adverse outcomes in the post-transplant period. 8 Application of sensitive solid phase antibody testing techniques using luminex platform increases the mean PRA levels in transplant recipients in spite of a decreased percentage of sensitized recipients. Induction and maintenance immunosuppression could be tailored differently in patients with different PRA level status. 23 CDC cross match is important because it helps in validating and predicting recipient-donor compatibility and the risk of AMR. 24 Pre transplantation anti HLA screening and cross match is necessary to avoid graft dysfunction after transplantation because often generation of allograft antibodies or de novo antibodies may results in graft dysfunction and cause AMR. The principle of HLA antibodies testing is the same however the methods and mechanism is different. 25 In solid phase assay, micro beads coated with a single HLA antigen are used. Beads are coated with a HLA phenotype in addition to differences in the actual composition and nature of proteins present in micro particles. It is important to say that the micro particles are individually different for different machines, however poor standardization is observed in these tests and therefore cut off MFI value have been found to very between different centers performing the same test. 8 Anti-HLA Class I and Anti-HLA Class II Control antibodies are chimeric human IgG1 monoclonal antibodies, which are validated to recognize all class I or class II HLA antigens. 26 In histocompatibility laboratories, the quantification of anti-HLA antibodies using solid phase techniques such as Luminex assays, face the problem of subjective cut-off values that do not take into account to runto-run and bead-to-bead variations. Standardization using proprietary anti-HLA control antibodies allows to accurately interpreting median fluorescence intensity (MFI) values in Luminex assays. This is essential for patient follow-up studies and the identification of weak antibodies from highly sensitized patients awaiting organ transplantation. HLA antibody screening and identification has traditionally been done by cell based techniques such as the Complement Dependent Cytotoxicity (CDC) assay or by cell based flow cytometric assays. Now most HLA labs can test antibody by the solid phase Luminex bead based assays. The advantages of SAB assays are the sensitivity and specificity of the results obtained. When using single antigen bead assays, for each antibody detected, a mean fluorescence intensity (MFI) value is obtained which provides a measure of the strength each antibody. Solid phase assays by Luminex for the desensitisation protocols help in identification of specificities of donor specific anti HLA antibody. 27 HLA antibody testing by the solid phase Luminex bead based assays is important for success in achieving desensitization in HLA-antibody incompatible transplantation. Pre transplant CDC cross match along with pre and post transplant anti-HLA antibody testing are very important to reduce the renal allograft rejection. 28 Donor specific anti-HLA antibody assays detect sensitisation and also help in monitoring the recipient for development of donor specific humoral response by donor specific antibody which could be associated with AMR. 29, 30 Post-transplant Anti-HLA antibody (DSA) detection is important because recipients on immunosuppression could still develop de novo antibodies which can cause graft dysfunction and damage transplanted allograft. 31 Single antigen bead assays have very low probability of giving false positive results. In solid-phase assays rarely disconnect can occur in specificities of anti HLA antibody detected. This could be due to alterations in SAB eHLA molecule during bead creation by biotechnology. 32 All assay based on micro particles coated HLA antigens beads are not giving same information, as the beads themselves, as well as the analytical platforms used to assess them, are not equivalent. But all solid-phase assays broadly correlate well with each other. 33 
Conclusion
In our study there were no strong correlation between DSA positivity and PRA screening. PRA screen negative group had less number of acute rejection episodes. Our experience with solid-phase anti-HLA screening platforms suggests improved assay sensitivity. The clinical utility of solid phase anti-HLA antibody detection serves as a powerful complement to standard cross-match test results. The Luminex-based single antigen bead (SAB) technology, which uses recombinant single HLA molecules, allows detection and characterization of HLA antibodies with greater sensitivity than CDC, PRA and lysate based DSA assay (Lifecodes, Gen-Probe). All these techniques require careful interpretation of results which is both challenging and needs experience in HLA antibody diagnostics. 34 
